REFERENCES
- Cazzola M, Malcovati L. Myelodysplastic syndromes – coping with ineffective hematopoiesis. N Engl J Med. 2005; 352(6):536–538.
- Greenberg P, Cox C, LeBeau MM, International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997; 89:2079–2088.
- Schafer AI, Cheron RG, Dluhy R, Clinical consequences of acquired transfusional iron overload in adults. N Engl J Med. 1981; 304(6):319–324.
- Malcovati L, Porta MG, Pascutto C, Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol. 2005; 23(30):7594–7603.
- Della Porta MG, Malcovati L, Travaglino E, A prognostic model for predicting the impact of comorbidities on survival of patients with myelodysplastic syndromes. Proceedings of the American Society of Hematology Meeting, Atlanta, December 2007. Blood. 2007; 110: (abstract 2453).
- Leithc HA, Goodman TA, Wong KK, Improved survival in patients with myelodysplastic syndrome (MDS) receiving iron chelation therapy. Proceedings of the American Society of Hematology Meeding, Orlando, December 2006. Blood. 108: (abstract 249).
- Rose C, Brechignac S, Vassilief D, Pierre Fenaux Groupe Francophone des Myelodysplasies (GFM). Positive impact of iron chelation therapy (CT) on survival in regularly transfused MDS patients. A prospective analysis by the GFM. Proceedings of the American Society of Hematology Meeting, Atlanta, December 2007. Blood. 2007; 110: (abstract 249).
- National Comprehensive Cancer network. NCCN Clinical practice guidelines. Myelodysplastic syndromes, v.2.2008. Available at http://www.nccn.org. http://www.nccn.org [2008].
- Valent P, Krieger O, Stauder R, Iron overload in myelodysplastic syndromes (MDS) – diagnosis, management, and response criteria: a proposal of the Austrian MDS platform. Eur J Clin Invest. 2008; 38(3):143–149.
- FDA news. FDA approves first oral drug for chronic iron overload. November 9, 2005. Accessed 23 March 2009 from: http://www.fda.gob/bbs/topics/news/2005/NEW01258.HTML. http://www.fda.gob/bbs/topics/news/2005/NEW01258.HTML [accessed March 23, 2009].
- Metzgeroth G, Dinter D, Schultheis B, Deferasirox in MDS patients with transfusion-caused iron overload – a phase-II study. Ann Hematol. 2009; 88(4):301–310.
- Kontoghiorghes GJ. Transparency and access to full information for the fatal or serious toxicity risks, low efficacy and high price of deferasirox, could increase the prospect of improved iron chelation therapy worldwide. Hemoglobin. 2008; 32(6):608–615.
- Angelucci E, Barosi G, Camaschella C, Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. Haematologica. 2008; 93(5):741–752.
- Mody-Patel N, Goldberg SL, Barghout V. Deferasirox for myelodysplastic syndrome patients with transfusional iron overload: A budget impact analysis. Proceedings of the American Society of Clinical Oncology Meeting, Chicago, June 2007, Part I. J Clin Oncol. 2007; 25(18S):17019.
- McLeod C, Fleeman N, Kirkham J, Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation. Health Technol Assess. 2009; 13(1):1–121.